ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Pesticides Not A Risk Factor For Long Island Breast Cancer, Study Finds

September 6, 2002

Cancer, AIDS Drug Screening Contracts Ok’d For Recompetition

February 28, 1992

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001

NTP Board Plans Peer Review Of Bioassay Reports

April 11, 1980

USPSTF Recommends Hepatitis C Screening For Baby Boomers

June 26, 2013

Brandt Tells NIK There May Be No Exceptions To DRG Regulations, Maybe a Few At Comprehensive Centers

June 24, 1983